Sunday, June 14, 2026
🇺🇸 FDA

Patent directory · USPTO A61K / A61P

Browse patents

Browse 30,257 pharma-relevant patents (US A61K/A61P) linked to tracked companies, drugs, and pipeline programs.

Patents indexed 30,257
Companies 1,769
Drugs linked 4,797

Quick answer

NovaPharmaNews indexes 30,257 US pharmaceutical patents from USPTO PatentsView (CPC A61K/A61P), cross-linked to company assignees, drug INN profiles, and pipeline programs. Search by patent number, applicant, title, or CPC code — or use facet hubs for expiring patents, assignees, and therapeutic areas.

Patent results

Page 976 of 1,261

  1. US 7867977

    Immunogenic peptides and methods of use for treating and preventing cancer

    The United States of America, as represented by the Department of Health and Human Services · Granted Jan 11, 2011 · Expires Jan 6, 2031

    granted

  2. US 7868013

    Cycloalkyl substituted pyrimidinediamine compounds and their uses

    Rigel Pharmaceuticals, Inc. · Granted Jan 11, 2011 · Expires Jan 6, 2031

    granted

  3. US 7868006

    Heterocyclic substituted piperazines with CXCR3 antagonist activity

    Pharmacopeia Drug Discovery, Inc. · Granted Jan 11, 2011 · Expires Jan 6, 2031

    granted

  4. US 7868176

    Salts of N-(4-fluorobenzyl)-N-(1-methylpiperidin-4-y1)-N′-(4-(2-methylpropyloxy)phenylmethyl)carbamide and their preparation

    ACADIA Pharmaceuticals Inc. · Granted Jan 11, 2011 · Expires Jan 6, 2031

    granted

  5. US 7868169

    Crystalline rosuvastatin intermediate

    TEVA PHARMACEUTICAL INDUSTRIES, LTD. · Granted Jan 11, 2011 · Expires Jan 6, 2031

    granted

  6. US 7868162

    Antimicrobial and antiviral compounds and methods for their use

    Lakewood Amedex, Inc. · Granted Jan 11, 2011 · Expires Jan 6, 2031

    granted

  7. US 7868160

    Compositions and methods for inhibiting expression of anti-apoptotic genes

    Alnylam Pharmaceuticals, Inc. · Granted Jan 11, 2011 · Expires Jan 6, 2031

    granted

  8. US 7867974

    Induction of tolerance by oral administration of factor VIII and treatment of hemophilia

    The United States of America, as represented by the Department of Health and Human Services · Granted Jan 11, 2011 · Expires Jan 6, 2031

    granted

  9. US 7867171

    Management of gastro-intestinal disorders

    EXALENZ BIOSCIENCE LTD. · Granted Jan 11, 2011 · Expires Jan 6, 2031

    granted

  10. US 7867515

    Orally disintegrating solid dosage forms comprising progestin and methods of making and use thereof

    Teva Womans's Health, Inc. · Granted Jan 11, 2011 · Expires Jan 6, 2031

    granted

  11. US 2011003857

    STABILIZED, ANTIMICROBIALLY EFFECTIVE COMPOSITION WITH A CONTENT OF BISPYRIDINIUM ALKANE

    AIR LIQUIDE SANTE INT [FR] · Granted Jan 6, 2011 · Expires Jan 1, 2031

    granted

  12. US 7863282

    Compositions useful as inhibitors of protein kinases

    Vertex Pharmaceuticals Incorporated · Granted Jan 4, 2011 · Expires Dec 30, 2030

    granted

  13. US 7863415

    Amino acid and peptide conjugates of amiloride and methods of use thereof

    The Regents of the University of California · Granted Jan 4, 2011 · Expires Dec 30, 2030

    granted

  14. US 7863421

    Polymer-factor VIII moiety conjugates

    Nektar Therapeutics · Granted Jan 4, 2011 · Expires Dec 30, 2030

    granted

  15. US 7862815

    Methods for inhibiting angiogenesis with inhibitors of proadrenomedullin N-terminal 20 peptide (PAMP)

    The United States of America, as represented by the Department of Health and Human Services · Granted Jan 4, 2011 · Expires Dec 30, 2030

    granted

  16. US 7862605

    Coated implantable medical device

    Cook Regentec LLC · Granted Jan 4, 2011 · Expires Dec 30, 2030

    granted

  17. US 7862811

    Protease inhibition for prevention or treatment of heart failure

    The Regents of the University of Colorado · Granted Jan 4, 2011 · Expires Dec 30, 2030

    granted

  18. US 7862820

    Immunoglobulin chimeric monomer-dimer hybrids

    Syntonix Pharmaceuticals, Inc. · Granted Jan 4, 2011 · Expires Dec 30, 2030

    granted

  19. US 7863041

    Rabies virus vector systems and compositions and methods thereof

    The United States of America as represented by the Secretary of the Department of Health and Human Services, Centers for Disease Control and Prevention · Granted Jan 4, 2011 · Expires Dec 30, 2030

    granted

  20. US 7863047

    Intracorporeal medicaments for photodynamic treatment of disease

    Provectus Pharmatech, Inc. · Granted Jan 4, 2011 · Expires Dec 30, 2030

    granted

  21. US 7863262

    Nitroxyl progenitors in the treatment of heart failure

    The United States of America, as represented by the Department of Health and Human Services · Granted Jan 4, 2011 · Expires Dec 30, 2030

    granted

  22. US 7863275

    Uses of tetrahydrobiopterin and derivatives thereof

    The Board of Regents of the University of Texas System · Granted Jan 4, 2011 · Expires Dec 30, 2030

    granted

  23. US 7863286

    Stereoisomerically enriched 3-aminocarbonyl bicycloheptene pyrimidinediamine compounds and their uses

    Rigel Pharmaceuticals, Inc. · Granted Jan 4, 2011 · Expires Dec 30, 2030

    granted

  24. US 7863414

    Methods of treatment and uses for CaMKII and its interaction with HDACs and calpain

    The Board of Regents of the University of Texas System · Granted Jan 4, 2011 · Expires Dec 30, 2030

    granted

Frequently asked questions

What patents are included in this directory?

We index 30,257 published US pharma-relevant patents filtered to CPC classes A61K and A61P, with assignee links to our company directory where a match exists.

How do I search for a patent?

Use the search box to match patent number, title, applicant name, or CPC classification (e.g. A61K). For cross-entity queries spanning news and drugs, use the global search.

How is this different from the patent intelligence dashboard?

The dashboard at /patents highlights expirations, recent grants, and assignee rankings. Browse is the full paginated directory with search — best for looking up a specific filing or applicant portfolio slice.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.